دورية أكاديمية
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
| العنوان: | Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes |
|---|---|
| المؤلفون: | Gagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovich |
| المصدر: | Сахарный диабет, Vol 20, Iss 4, Pp 286-298 (2017) |
| بيانات النشر: | Endocrinology Research Centre, 2017. |
| سنة النشر: | 2017 |
| المجموعة: | LCC:Nutritional diseases. Deficiency diseases |
| مصطلحات موضوعية: | diabetes mellitus, type 2, glucagon-like peptide-1, glucagon-like peptide-1 receptor, hypoglycemic agents, incretins, Nutritional diseases. Deficiency diseases, RC620-627 |
| الوصف: | Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of antidiabetic drugs developed over the past 15 years. GLP-1, a gastrointestinal peptide hormone that contributes to the postprandial “incretin effect”, stimulates glucose-dependent insulin secretion. The incretin effect is greatly diminished in type 2 diabetes, but can be restored by GLP-1RAs. These drugs also exert other GLP-1 effects, including reducing glucagon secretion, delaying gastric emptying, reducing food intake, improving cardiac ventricular function, and lowering blood pressure. Short-acting GLP-1RAs are administered once daily (lixisenatide) or twice daily (exenatide); long-acting GLP 1RAs are administered once daily (liraglutide) or once weekly (slow-release exenatide, dulaglutide, albiglutide). All GLP-1RAs significantly reduce glycated hemoglobin (HbA1c) in patients with type 2 diabetes whose glycemic control is inadequate with oral antidiabetic drugs. Compared with other antidiabetic medications, GLP-1RAs provide better glycemic control with the additional benefit of weight loss. Within this class, long-acting GLP-1RAs are more efficacious than short-acting GLP-1RAs, with similar or lower risk of hypoglycemia and lower incidence of gastrointestinal adverse effects. Head-to-head trials and a network meta-analysis suggest that once daily liraglutide is the most effective GLP-1RA in reducing HbA1c. Dulaglutide is the only once-weekly GLP 1RA demonstrated to be noninferior to liraglutide. The once-weekly GLP-1RAs offer additional advantages to patients, including fewer injections and easy-to-use, single-dose pen devices. Despite the relatively recent development of GLP-1RAs, international diabetes guidelines recognize the benefits of this class of drugs and recommend them as a treatment option for patients with type 2 diabetes. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English Russian |
| تدمد: | 2072-0351 2072-0378 |
| العلاقة: | https://www.dia-endojournals.ru/jour/article/view/8804Test; https://doaj.org/toc/2072-0351Test; https://doaj.org/toc/2072-0378Test |
| DOI: | 10.14341/DM8804 |
| الوصول الحر: | https://doaj.org/article/a1353861504246f5877ed418350e4d42Test |
| رقم الانضمام: | edsdoj.1353861504246f5877ed418350e4d42 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 20720351 20720378 |
|---|---|
| DOI: | 10.14341/DM8804 |